In recent years, significant progress has been made in tumor immunotherapy with immune checkpoint inhibitors (ICIs), particularly Programmed Cell Death Protein-1 (PD-1)/Programmed Cell Death-Ligand 1 (PD-L1) inhibitors. This evidence concerns the gene CD274 and neoplasm.